{"DataElement":{"publicId":"2680980","version":"1","preferredName":"Post Donor Cellular Infusion Acute Graft Versus Host Disease Maximum Overall Grade","preferredDefinition":"Post; occuring after._A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation._A syndrome of immologically mediated tissue damage occurring following allogeneic transplant usually affecting the skin, liver, and gi tract.  Onset is usually within one hundred days of transplantation or immunologic manipulation._The largest possible quantity or degree._Including everything._A position on a scale of intensity or amount or quality.","longName":"PO_DCI_AGVHD_OV_GR","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2680976","version":"1","preferredName":"Post Donor Cellular Infusion Acute Graft Versus Host Disease Maximum Grade","preferredDefinition":"Post; occuring after._A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation._A syndrome of immologically mediated tissue damage occurring following allogeneic transplant usually affecting the skin, liver, and gi tract.  Onset is usually within one hundred days of transplantation or immunologic manipulation._The largest possible quantity or degree._A position on a scale of intensity or amount or quality.","longName":"PO_DCI_AC_GVHD_MA_GR","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2793672","version":"1","preferredName":"Post Donor Cellular Infusion Acute Graft Versus Host Disease","preferredDefinition":"Post; occuring after.:A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.:A syndrome of immologically mediated tissue damage occurring following allogeneic transplant usually affecting the skin, liver, and gi tract.  Onset is usually within one hundred days of transplantation or immunologic manipulation.","longName":"C38008:C77273:C4980","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Donor Cellular Infusion","conceptCode":"C77273","definition":"A form of adoptive immunotherapy used after hematopoietic stem cell transplantation (HSCT). Lymphocytes from the original stem cell donor are given to the HSCT recipient, after the transplant, to augment an antitumor immune response (graft-versus-tumor), or ensure that the donor stem cells remain engrafted. Although lymphocytes are the most commonly used cell, other cells including fibroblasts, mesenchymal or dendritic cells may be delivered to affect chimerism, treat Graft vs. Host Disease, treat viral infections or Post Transplant Lymphoproliferative Disease or other novel uses under investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Acute Graft Versus Host Disease","conceptCode":"C4980","definition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, usually affecting the skin, liver, and GI tract. The onset is usually within one hundred days of transplantation or immunologic manipulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"58E7C313-996F-4361-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-10-10","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-10-10","modifiedBy":"ONEDATA","dateModified":"2008-10-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2512722","version":"1","preferredName":"Maximum Grade","preferredDefinition":"The largest possible quantity or degree.:A position on a scale of intensity or amount or quality.","longName":"C25564:C48309","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Maximum","conceptCode":"C25564","definition":"The largest possible quantity or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Grade","conceptCode":"C48309","definition":"A position on a scale of intensity or amount or quality.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B8A6DFC-4661-280D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"39F4444C-2DFE-6B4F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-12","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-09-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2680968","version":"1","preferredName":"Acute Graft Versus Host Disease Overall Grade","preferredDefinition":"A syndrome of immologically mediated tissue damage occurring following allogeneic transplant usually affecting the skin, liver, and gi tract.  Onset is usually within one hundred days of transplantation or immunologic manipulation._Including everything._A position on a scale of intensity or amount or quality.","longName":"AGVHD_OVALL_GD","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"22","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Present, grade unknown","valueDescription":"AGVHD present, Grade unknown","ValueMeaning":{"publicId":"2685126","version":"1","preferredName":"AGVHD present, Grade unknown","longName":"2685126","preferredDefinition":"AGVHD present, severity unknown","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B892A58-E4F5-7394-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-02","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-10-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B892A58-E50E-7394-E044-0003BA3F9857","beginDate":"2007-10-02","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-10-02","modifiedBy":"JOSHUAT","dateModified":"2007-10-02","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"AGVHD Grade Unknown","ValueMeaning":{"publicId":"2685127","version":"1","preferredName":"AGVHD Grade Unknown","longName":"2685127","preferredDefinition":"Severity unknown","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B892A58-E51A-7394-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-02","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-10-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B892A58-E533-7394-E044-0003BA3F9857","beginDate":"2007-10-02","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-10-02","modifiedBy":"JOSHUAT","dateModified":"2007-10-02","deletedIndicator":"No"},{"value":"0","valueDescription":"AGVHD Grade 0","ValueMeaning":{"publicId":"2793630","version":"1","preferredName":"AGVHD Grade 0","longName":"2793630","preferredDefinition":"NO Degree of Organ Involvement","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"58D4E828-A735-5032-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-10-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"58D4E828-A74E-5032-E044-0003BA3F9857","beginDate":"2007-10-02","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-10-09","modifiedBy":"CZECHS","dateModified":"2008-10-09","deletedIndicator":"No"},{"value":"I","valueDescription":"AGVHD Grade  I","ValueMeaning":{"publicId":"2793631","version":"1","preferredName":"AGVHD Grade  I","longName":"2793631","preferredDefinition":"At least stage 1-2 skin, with no liver and no gut involvement.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"58D4E828-A75A-5032-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-10-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"58D4E828-A773-5032-E044-0003BA3F9857","beginDate":"2007-10-02","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-10-09","modifiedBy":"CZECHS","dateModified":"2008-10-09","deletedIndicator":"No"},{"value":"II","valueDescription":"AGVHD Grade  II","ValueMeaning":{"publicId":"2793632","version":"1","preferredName":"AGVHD Grade  II","longName":"2793632","preferredDefinition":"At least stage 3 skin OR stage 1 liver OR stage 1 gut.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"58D4E828-A77F-5032-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-10-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"58D4E828-A798-5032-E044-0003BA3F9857","beginDate":"2007-10-02","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-10-09","modifiedBy":"CZECHS","dateModified":"2008-10-09","deletedIndicator":"No"},{"value":"III","valueDescription":"AGVHD Grade  III","ValueMeaning":{"publicId":"2793633","version":"1","preferredName":"AGVHD Grade  III","longName":"2793633","preferredDefinition":"At least stage 2-3 for liver or stage 2-4 for gut.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"58D4E828-A7A4-5032-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-10-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"58D4E828-A7BD-5032-E044-0003BA3F9857","beginDate":"2007-10-02","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-10-09","modifiedBy":"CZECHS","dateModified":"2008-10-09","deletedIndicator":"No"},{"value":"IV","valueDescription":"AGVHD Grade  IV","ValueMeaning":{"publicId":"2793634","version":"1","preferredName":"AGVHD Grade  IV","longName":"2793634","preferredDefinition":"At least stage 4 skin, or stage 4 liver or lessor organ involvement with an extreme decrease in performance status.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"58D4E828-A7C9-5032-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-10-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"58D4E828-A7E2-5032-E044-0003BA3F9857","beginDate":"2007-10-02","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-10-09","modifiedBy":"CZECHS","dateModified":"2008-10-09","deletedIndicator":"No"},{"value":"Not applicable","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"5035616","version":"1","preferredName":"Not Applicable","longName":"5035616","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"223B305D-E0E3-6C83-E050-BB89AD433DFD","latestVersionIndicator":"Yes","beginDate":"2015-10-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-10-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2340DD99-4AF1-5DFA-E050-BB89AD431154","beginDate":"2015-10-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-10-29","modifiedBy":"ONEDATA","dateModified":"2015-10-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2785783","version":"1","preferredName":"Acute Graft Versus Host Disease Overall Grade","preferredDefinition":"A syndrome of immologically mediated tissue damage occurring following allogeneic transplant usually affecting the skin, liver, and gi tract.  Onset is usually within one hundred days of transplantation or immunologic manipulation.:Including everything.:A position on a scale of intensity or amount or quality.","longName":"C4980:C25605:C48309","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Graft Versus Host Disease","conceptCode":"C4980","definition":"A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, usually affecting the skin, liver, and GI tract. The onset is usually within one hundred days of transplantation or immunologic manipulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Overall","conceptCode":"C25605","definition":"Including everything.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Grade","conceptCode":"C48309","definition":"A position on a scale of intensity or amount or quality.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5719E926-F26B-27FA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-17","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-09-17","modifiedBy":"ONEDATA","dateModified":"2008-09-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"39F41B3F-2865-3FEC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2007-09-12","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-09-12","modifiedBy":"KUMMEROA","dateModified":"2016-02-24","changeDescription":".Added PV for 2100r4. AK 10/29/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964925","version":"1","longName":"2450r1: Post-TED","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"post_ted_dci_agvhd_grd","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedClinicalInterpretation:value","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Maximum grade of Acute Graft","type":"Preferred Question Text","description":"Maximum grade of Acute Graft Versus Host Disease after this DCI?","url":null,"context":"NHLBI"},{"name":"Maximum grade of acute graft versus host disease:","type":"Alternate Question Text","description":"Maximum grade of acute graft versus host disease:","url":null,"context":"NHLBI"},{"name":"Journal article with Acute GVHD grades \"Bone Marrow Transplant 1995 Jun;15(6):825-8\".","type":"REFERENCE","description":"Journal article with Acute GVHD grades \"Bone Marrow Transplant 1995 Jun;15(6):825-8\".","url":null,"context":"NHLBI"},{"name":"BRIDG mapping for CDE:2680980","type":"BRIDG Mapping Path","description":"PerformedObservation > PerformedClinicalInterpretation.value WHERE PerformedObservation > AssessedResultRelationship > PerformedDiagnosis.value = \"GVHD\" AND PerformedDiagnosis.diseaseStatusCode = \"Acute\" AND  PerformedObservation > DefinedObservation.nameCode = \"assess grade\" AND PerformedClinicalInterpretation.value IS MAXIMUM AND PerformedObservation.dateRange IS GREATER THAN {infusion date}  {infusion date} is determined by: Subject > PerformedSubstanceAdministration.dateRange WHERE PerformedSubstanceAdministration > DefinedSubstanceAdministration.nameCode = \"Administer donor cellular infusion(DCI)\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"39F4444C-2E11-6B4F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-12","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-09-12","modifiedBy":"ALEYR","dateModified":"2019-04-07","changeDescription":". .1/8/14mn-added Bridg info.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}